Mineralys Therapeutics Secures Up to $500 Million Loan and Gains Full Lorundrostat Rights

Corporate Action
โดย Insider Monkey·Read original
Summary · why it matters

Mineralys Therapeutics has amended its agreement with Tanabe Pharma to obtain full worldwide rights to lorundrostat without future royalties, paying a $200 million upfront cash payment and up to $365 million in additional payments upon achieving certain commercial targets. The company also secured a loan of up to $500 million from funds managed by Pharmakon Advisors, provided in stages tied to FDA approval of lorundrostat and sales milestones. This financing will support growth and commercialization but increases debt obligations, potentially limiting financial flexibility. Goldman Sachs analyst Richard Law reiterated a Buy rating on the stock with a $42 target price on June 4.

Impact on stocks 2

Health Care▲ · 1 stocks
Financials▲ · 1 stocks

Off-coverage companies 2

Mitsubishi Tanabe Pharma CorporationPrivate▼ Negative
Capitalrelevance

Tanabe Pharma gave up future royalties on lorundrostat in exchange for upfront and milestone payments, losing potential long-term revenue.

Pharmakon Advisors, LPPrivate± Mixed
relevance

© 2026 MarketDXNews